This retrospective study compared the efficacy and safety of transarterial chemoembolization (TACE) combined with sunitinib versus sunitinib alone in treating 98 patients with unresectable advanced renal cell carcinoma (RCC). The TACE + sunitinib group showed significantly higher objective response rate (ORR), disease control rate (DCR), and longer overall survival (OS) and progression-free survival (PFS) compared to the sunitinib-only group. While the TACE + sunitinib group experienced a higher incidence of abdominal pain, fever, and vomiting (post-embolization syndrome), the combination therapy was deemed safe and effective.
Publisher
BMC Cancer
Published On
Mar 20, 2023
Authors
Chuansheng Zheng, Haohao Lu, Qing Ye, Li Fan, Xiangwen Xia
Tags
transarterial chemoembolization
sunitinib
renal cell carcinoma
objective response rate
overall survival
safety
combination therapy
Related Publications
Explore these studies to deepen your understanding of the subject.